MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Retained Earnings · Q3 FY2026 · quarter ended Sep 2026
Retained earnings remains negative
Q3 FY2026 retained earnings was -$347.51M, compared with -$202.41M a year earlier.
Context
- Retained earnings amounted to 69.4% of total assets at the end of Q3 FY2026, up 18.8 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -71.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (224.48M) USD
- Year-over-year change
- -63.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (224.48M) | -63.2% |
| FY2024 | 2024-12-31 | (137.51M) | -81.9% |
| FY2023 | 2023-12-31 | (75.58M) | -75.7% |
| FY2022 | 2022-12-31 | (43.02M) | — |
Retained Earnings vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -71.7% is the 7th highest of 8, against a peer median of -10.8%.
- Retained earnings amounts to 69.4% of total assets for MBX, versus a peer median of 185.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$85.12M USD | +53.8% | — | 31.7% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | -$347.51M USD | -71.7% | — | 69.4% |
| Mar 2026 | -$461.46M USD | -10.8% | — | 994.9% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | -$558.84M USD | — | — | 46.1% |
| Mar 2026 | -$669.07M USD | +1.8% | — | 170.7% | |
| Mar 2026 | -$672.05M USD | -15.7% | — | 200.2% | |
| Jun 2026 | -$1.13B USD | -89.3% | — | 217.3% | |
| Sep 2026 | -$1.5B USD | -14.9% | — | 338.1% | |
| Sep 2026 | -€1.84B EUR | +32.0% | — | 75.8% | |
| Peer median (excluding MBX) | — | -10.8% | — | 185.5% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.